The Immunology Core (Core E) provides immunologic assays, reagents and expertise to support innovative aasic, clinical and translational HIV/AIDS research by Penn CFAR members, with the overall goal of improving our understanding of the pathogenesis and immunopathogenesis of HIV infection and AIDS; introducing new approaches for investigating immune function;developing novel immunotherapy or gene therapy strategies for viral control or immune reconstitution;and basic discovery and translational development of vaccine strategies. To support this mission, the Immunology Core offers a wide range of services to benefit all CFAR members performing HIV related immunoldgical research: (1) """"""""Self-service"""""""" support including validated reagents and materials that are widely used among the member labs, including purified primary human blood cell subsets and Qdot labeled antibodies for polychromatic flow cytometry;(2) """"""""Full service"""""""" support that performs standard immunological assays using AACTG and PACTG approved protocols on samples provided by CFAR members;flow cytometric-based assays including phenotyping and intracellular cytokine measurements;and a BSL3 sorting facility enabling """"""""live"""""""" sorts of infectious material, and;(3) Training, education and support in the use of reagents, assays, or techniques, as well as consultation and collaboration for immunology-based projects. In the coming cycle, we will provide the CFAR community with access and expertise to use an exciting new human immune system mouse with which to study HIV-1 pathogenesis and vaccines in an in vivo model.
HIV-1 is a virus that attacks the immune system. Having access to key immunological reagents, assays and expertise will allow Penn CFAR investigators to make more rapid progress in understanding the underlying cause of HIV-1 pathogenesis and to evaluate new therapies or vaccines to fight or prevent HIV-1 infection.
|MacBrayne, Christine E; Marks, Kristen M; Fierer, Daniel S et al. (2018) Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother 73:2112-2119|
|Veenhuis, Rebecca T; Kwaa, Abena K; Garliss, Caroline C et al. (2018) Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight 3:|
|Ecker, Christopher; Guo, Lili; Voicu, Stefana et al. (2018) Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Rep 23:741-755|
|Schnoll, Robert A; Thompson, Morgan; Serrano, Katrina et al. (2018) Rate of Nicotine Metabolism and Tobacco Use among Persons with HIV: Implications for Treatment and Research. J Acquir Immune Defic Syndr :|
|Loy, Dorothy E; Rubel, Meagan A; Avitto, Alexa N et al. (2018) Investigating zoonotic infection barriers to ape Plasmodium parasites using faecal DNA analysis. Int J Parasitol 48:531-542|
|Kendall, Jacob; Anglewicz, Philip (2018) Migration and health at older age in rural Malawi. Glob Public Health 13:1520-1532|
|Liu, Wei; Krump, Nathan A; MacDonald, Margo et al. (2018) Merkel Cell Polyomavirus Infection of Animal Dermal Fibroblasts. J Virol 92:|
|Plenderleith, Lindsey J; Liu, Weimin; MacLean, Oscar A et al. (2018) Adaptive Evolution of RH5 in Ape Plasmodium species of the Laverania Subgenus. MBio 9:|
|Colón, Krystal; Speicher, David W; Smith, Peter et al. (2018) S100a14 is Increased in Activated Nk Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-Nk crosstalk. J Acquir Immune Defic Syndr :|
|Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104|
Showing the most recent 10 out of 775 publications